Q-omics provides the consensus-scored MOB3C profile across patient tissues and cancer cell-line models. MOB3C expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MOB3C is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, MOB3C RNA expression shows 19,448 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, HNSC, and UVM as cancer lineages where MOB3C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MOB3C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MOB3C survival associations across molecular data types. MOB3C RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MOB3C RNA expression–survival associations across cancer types. High MOB3C expression shows unfavorable associations in LGG and LIHC, but favorable associations in SKCM, KIRC, MESO and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MOB3C RNA expression.
This table summarizes MOB3C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MOB3C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MOB3C shows lower tumor expression in LUAD, KICH, UCEC and BRCA and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher MOB3C RNA expression in tumor versus normal tissue (log2 FC = +1.044, t-test p < 0.001).
This table shows molecular features associated with MOB3C in patient tissues and cancer cell lines. In patient samples, MOB3C shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MOB3C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
